Nuwellis posted an updated investor presentation on November 17, 2026, reporting 13% year-to-date revenue growth, gross margin of 72% versus 59% a year earlier, and cash runway through Q2 2027.
NUWE · Nuwellis, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, including continued operating losses, negative cash flows from operations, an accumulated deficit of $327.7 million, and the need for additional capital to fund ongoing operations and growth initiatives (including the integration of Rendiatech Ltd., an Israeli company (“Rendiatech”) following the Company’s acquisition), raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the date these financial statements are issued. While management’s plans, including recent financing activities, cost discipline initiatives, and contingency measures, are intended to address these conditions, such plans do not alleviate the substantial doubt.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 11%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Oct 2020 to Nov 2026
Up next
Latest documents
Nuwellis raised approximately $6.7 million through a registered direct offering and concurrent Series C warrant exercises. Cash, cash equivalents and restricted cash totaled $8.4 million as of September 30, 2026, supporting operations through the second quarter of 2027.
Nuwellis reported third-quarter net sales of $2.2 million, operating loss improved 24% to $2.1 million, gross margin expanded to 69.5%, and cash and cash equivalents reached $8.3 million as of September 30, 2026.
Nuwellis approved a one-for-nine reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on October 26, 2026. Shares will trade split-adjusted on the Nasdaq Capital Market under NUWE starting October 27, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. Nuwellis (NUWE) reported Q2 2026 revenue of $2.0 million, up 14% year-over-year with U.S. revenue up 17%, while gross margin expanded to 76% from 56% and the installed base grew with 24 consoles sold in the first half versus 5 a year earlier; the company also raised approximately $12.7 million in gross proceeds, appointed a new CEO, and advanced the proposed Aquadex pediatric label expansion following an FDA pre-submission meeting.
- + Q2 revenue grew 14% YoY to $1.97 million, with U.S. revenue up 17% and H1 revenue up 20%
- + Gross margin expanded to 76% from 56% on pricing, mix, and contract manufacturing
- + Installed base grew sharply, with 24 consoles sold in H1 versus 5 in H1 2025
- + Raised approximately $12.7 million in gross proceeds, including $6.0 million in June and ~$6.7 million post-quarter
- + Pediatric footprint expanded into two new states (Michigan and Wisconsin) plus additional South Carolina system
- − Q2 net loss was $4.8 million, though narrower than the $12.6 million prior-year loss
- − Operating expenses rose to $4.7 million in Q2 from $3.9 million a year ago
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Aquadex consoles sold | 32 | first nine months of 2026 | — |
| Gross margin | 71.7% | year-to-date 2026 (nine months ended September 30, 2026) | — |
| Shares sold under ATM | 134,488 | the three months ended September 30, 2026 filing | — |
| consoles sold | 24 | first half of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUWE
this stock
Nuwellis, Inc.
|
$2.06M | — | -5.4% | — | 36.2% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 34
Nuwellis posted an updated investor presentation on November 17, 2026, reporting 13% year-to-date revenue growth, gross margin of 72% versus 59% a year earlier, and cash runway through Q2 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUWE | -24.3% | +632.7% | -85.9% | -32.9% | -93.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -18.8% | +639.0% | -80.2% | -27.7% | -98.7% |